FDA'S DTC Task

In the weeks since the Food and Drug Administration told 23andMe that it must cease marketing its personal genome service there has been quite a bit of chatter about how the agency is being overly cautious, or too paternalistic, grinding up the gears of a fledgling industry while telling the American public that it knows better than them about what health information they can handle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.